Atara Biotherapeutics, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Anhco Nguyen
- Full Time Employees
- 153
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 611 Gateway Boulevard South San Francisco CA United States of America 94080
- IPO Date
- Oct 16, 2014
- CIK
- 0001604464
- Website
- atarabio.com
- Similar Companies
- Business
- Atara Biotherapeutics, Inc. (Nasdaq: ATRA) develops off-the-shelf allogeneic T-cell immunotherapies targeting Epstein-Barr virus (EBV)-associated diseases, cancer and autoimmune conditions; its lead product, tabelecleucel (tab-cel or EBVALLO), is an EBV-specific T-cell immunotherapy approved in Europe, the UK and Switzerland for EBV-positive post-transplant lymphoproliferative disease (EBV+ PTLD) in patients aged two years and older after at least one prior therapy, with the US FDA granting Priority Review to its Biologics License Application and a PDUFA target action date of January 10, 2026. The company's pipeline features next-generation allogeneic CAR T therapies including ATA3219, a CD19-targeted CAR T with 1XX co-stimulatory domain, memory phenotype and unedited T-cell receptor in Phase 1 for relapsed/refractory B-cell non-Hodgkin's lymphoma, lupus nephritis and systemic lupus erythematosus; ATA3431, a preclinical dual CD19/CD20 CAR T for B-cell malignancies and autoimmune diseases; and additional undisclosed preclinical AlloCAR T programs addressing oncology and autoimmune indications. Founded in 2012 and headquartered in Thousand Oaks, California, Atara leverages its EBV T-cell platform for scalable manufacturing from healthy donors, enabling rapid delivery without gene editing or HLA matching, with global operations transitioned substantially for tab-cel commercialization through its expanded partnership with Pierre Fabre Laboratories, which closed in late 2023 and includes up to $640 million in milestones, double-digit royalties and assumption of manufacturing, regulatory, clinical and commercial activities including US BLA sponsorship completed in October 2025, unlocking a $40 million milestone upon FDA approval. Recent developments encompass a 29% workforce reduction in October 2025 to retain 15 essential employees amid 60% projected operating expense cuts for 2025, board changes appointing Greg Ciongoli as Chair and adding James Huang and Nachi Subramanian while parting with three directors, a $36 million registered direct offering in September 2024, a non-binding $15 million equity line term sheet with Redmile Group, and resumed evaluation of strategic alternatives including potential mergers or acquisitions to maximize shareholder value.
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 22, 2026 in Atara Biotherapeutics, Inc. Lawsuit - ATRA
ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
ATRA Deadline: Rosen Law Firm Urges Atara Biotherapeutics, Inc. (NASDAQ: ATRA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
ATRA DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 22 Deadline in Securities Class Action - ATRA
ATRA FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026
ATARA DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
ATRARA (NASDAQ:ATRA) DEADLINE MAY 22nd: Bragar Eagel & Squire, P.C. Reminds Atara Biotherapeutics, Inc. Investors They Have Until May 22nd to Seek Lead Plaintiff Role in Class Action Lawsuit
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain Officers - ATRA
Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ATRA EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026
ATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - ATRA
Deadline Soon: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
DEADLINE ALERT: Atara Biotherapeutics (ATRA) Investors Who Suffered Losses Encouraged to Contact Faruqi & Faruqi Before May 22, 2026 Securities Class Action Deadline
Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your Rights - ATRA
ATARA DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ATRA